Mycenax Biotech Inc.

Business of CDMO services expands to Korea market.

TuNEX(ENIA11) gets approval for the first new biological entity market authorization from TFDA.

Fill/Finishing line was upgraded, and increased a new container cartridge aseptic line. Business of CDMO services expands to China market.

Business of CDMO services expands to the US market.

Mycenax in-house MBICHO medium has been innovated for improving the competitive capacity of CDMO services.

The third manufacturing line started to construct.

Mycenax signed an agreement of contract manufacturing biologics with an Australian biopharma. Business of CDMO services expands to Australia market.

Development project of LusiNEX received grants from MEA.

Mycenax signed an agreement of contract manufacturing biologics with Japanese biopharma. CDMO services expand to Japan market.

Completed construction of 2000L bioreactor as the first in Taiwan.。

Mycenax Cooperate stock was officially listed on Stock Exchange at Dec. 25, 2013.

Mycenax began the development project of LusiNEX.

Mycenax received PIC/S GMP certificate from TFDA.

TuNEX received a silver award of Pharmaceutical Technology Research and Development Award from TFDA.

Mycenax signed an agreement of contract manufacturing biologics with European biopharma. CDMO services expanded to the EU market.

Mycenax partnered with TSH Biopharm, for TSH to be responsible for phase III clinical trial and NDA submission, and Myce

TFDA approved phase III clinical trial of TuNEX in Taiwan.

TuNEX received approval to enter phase III clinical trial from Korea FDA.

Mycenax received a bronze award of Taiwan Biotech industry Awards.

Mycenax was registered as the listed company at the emerging stock market. Mycenax was categorized formally as biopharmaceutical company by MEA.

Started to conduct the second tier of MEA Industrial TDP, from Aug. 2008 -

TuNEX was approved to enter phase I/II clinical trial.

The development project of GranNEX started to conduct and was supported by MEA Industrial TDP.

Issued the IPO (4726).

Mycenax conducted Follow-on Biologics project granted by MEA for TuNEX pre-clinical development from Aug. 2005 to Jul. 2

Registered DMF to FDA (DMF no.17981)

Completed construction of biologics plant in Jhunan Science Park.

Established and installed in Jhunan Science Park.

Myceanx was established in Xindian Dist., New Taipei City.